CryoPort (NASDAQ:CYRX) Sets New 12-Month High After Analyst Upgrade

Key Points

• CryoPort reached a new 52-week high after KeyCorp raised its price target from $17 to $20 and maintained an Overweight rating. Shares traded as high as $19.29, up from the prior close of $16.05.
• Third-quarter revenue rose 14% year over year to $50.2 million, beating estimates, and CryoPort raised its 2026 revenue outlook to $197 million–$199 million. However, its $0.25-per-share loss was greater than analysts expected.
• Analyst sentiment is broadly positive: seven analysts rate the stock Buy and two rate it Hold, for a consensus “Moderate Buy” rating and an average price target of $21.69.

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) hit a new 52-week high during mid-day trading on Friday after KeyCorp raised their price target on the stock from $17.00 to $20.00. KeyCorp currently has an overweight rating on the stock. CryoPort traded as high as $19.29 and last traded at $18.7240, with a volume of 200,535 shares. The stock had previously closed at $16.05.

Several other equities research analysts have also recently commented on the company. Roth Capital reissued a "buy" rating and set a $21.00 target price on shares of CryoPort in a report on Friday, August 7th. Robert W. Baird set a $26.00 target price on CryoPort in a research report on Tuesday, October 13th. Weiss Ratings raised CryoPort from a "sell (d)" rating to a "hold (c-)" rating in a research note on Thursday, October 8th. Guggenheim boosted their price objective on CryoPort from $16.00 to $19.00 and gave the stock a "buy" rating in a research note on Thursday, October 1st. Finally, Piper Sandler upgraded CryoPort to a "buy" rating in a report on Tuesday, October 13th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $21.69.

Insiders Place Their Bets

In other CryoPort news, CEO Jerrell Shelton sold 28,800 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $14.91, for a total value of $429,408.00. Following the completion of the sale, the chief executive officer owned 1,201,814 shares in the company, valued at $17,919,046.74. This represents a 2.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 9.50% of the company's stock.

Trending Headlines about CryoPort

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: KeyCorp raised its price target to $20 from $17 and maintained an Overweight rating. Needham lifted its target to $28 from $19 and kept its Buy rating. Read More. Read More.
• Positive Sentiment: Third-quarter revenue grew 14% year over year to $50.2 million, topping analysts’ expectations of $48.66 million. Commercial cell and gene therapy revenue increased 20%. CryoPort also raised its 2026 revenue outlook to $197 million–$199 million and reported supporting a record 788 clinical trials and 23 commercially approved therapies. Read More.
• Negative Sentiment: The company reported a Q3 loss of $0.25 per share, missing consensus estimates of a loss of $0.18–$0.19 and worsening from a loss of $0.18 a year earlier. Read More.

Institutional Trading of CryoPort

Several hedge funds and other institutional investors have recently modified their holdings of CYRX. State of Wyoming acquired a new stake in CryoPort during the third quarter valued at $81,000. Counterpoint Mutual Funds LLC acquired a new position in CryoPort in the 3rd quarter worth about $324,000. State of Alaska Department of Revenue acquired a new position in CryoPort in the 3rd quarter worth about $40,000. Engineers Gate Manager LP purchased a new stake in shares of CryoPort during the 2nd quarter worth about $518,000. Finally, Squarepoint Ops LLC raised its stake in shares of CryoPort by 685.1% during the 2nd quarter. Squarepoint Ops LLC now owns 368,424 shares of the company's stock worth $5,784,000 after purchasing an additional 321,497 shares in the last quarter. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

CryoPort Stock Performance

The company has a market capitalization of $976.33 million, a PE ratio of -21.47 and a beta of 1.89. The stock has a 50 day moving average price of $16.93 and a two-hundred day moving average price of $13.42.

CryoPort (NASDAQ:CYRX - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07). CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.20%. The firm had revenue of $50.22 million during the quarter, compared to the consensus estimate of $48.66 million. Sell-side analysts predict that CryoPort, Inc. will post -0.83 earnings per share for the current year.

About CryoPort

CryoPort, Inc NASDAQ: CYRX provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of biological materials, including cell and gene therapies, vaccines, biologics, reproductive materials and other temperature-sensitive products.

Its offerings include cryogenic and refrigerated shipping containers, biological material storage, transportation logistics, shipment monitoring and related supply chain management services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.